Affiliate disclosure

Prepared by: Research Desk. Sources are linked for verification.
KlowSignal is a research-only reference site. It has one commercial relationship: an affiliate arrangement with Purita, a store that sells peptides for laboratory research use only.
How the paid links work
Some pages contain links to Purita's website that carry a tracking code. If a purchase is made after following one of these links, KlowSignal may earn a commission. The price paid by the buyer is the same with or without the link.
Each paid link is followed by a short "Affiliate disclosure" note on the page, and is marked in the page code as sponsored.
What the relationship does not change
- Purita does not review, approve or edit any content on this site.
- The commission does not affect which studies or regulatory records are reported, or how they are described.
- A link is not an endorsement and is not a statement about the quality of any product.
What this site says about Purita
Statements about Purita are limited to what can be checked on Purita's own website. Its product pages carry the label "For Research Use Only. Not for human or animal administration.", and it publishes a certificates page with batch documentation for some products.
Research use only
Products sold by research suppliers are intended for laboratory research. Nothing on this site describes or encourages human or animal use. See the research-only notice.
Contact
Questions about this disclosure: info@zvezdaff.com.
Last updated: 21 October 2026.
More from KlowSignal
How to read a research or regulatory signal
What a cell study, a phase 3 trial, a press release or an FDA list entry can and cannot tell you, with key regulatory vocabulary and a checklist for each signal.
FDA compounding committee, July 2026: seven research peptides on the agenda
FDA's Pharmacy Compounding Advisory Committee agenda for 23–24 July 2026 lists BPC-157, KPV, TB-500, MOTs-C, emideltide (DSIP), Semax and Epitalon. Here is what the record says.
Elamipretide (SS-31): the 2025 accelerated approval on the record
SS-31 is a Szeto-Schiller tetrapeptide studied for its binding to cardiolipin. In September 2025 FDA granted accelerated approval to elamipretide for Barth syndrome. Here is what the record shows.


